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Behavioral outburstPurpose: Anti-N-methyl-D-aspartate (NMDA) receptor antibody encephalitis is an autoimmune disorder mani-
festing subacutely with prominent aberrant movements and psychiatric symptoms. The clinical course is one
of progressive clinical deterioration that can be halted and often reversed by early diagnosis and treatment.
Patterns of presentation and etiology of anti-NMDA-receptor antibody encephalitis are dependent on age and
can be challenging to recognize in very young children.
Reports: Sequential clinical case observations of anti-NMDA-receptor antibody encephalitis presenting in very
young childrenwere examined over a year at a single tertiary pediatric institution. Cerebrospinal ﬂuid conﬁrmed
anti-NMDA-receptor antibodies in two cases (a 21-month-old boy and a 29-month-old girl) that demonstrated
either bizarre behavioral patterns or status epilepticus both associated with progressive deterioration. Once
recognized, the clinical course was arrested and reversed by aggressive treatment with plasma exchange,
immunoglobulin, and high dose IV steroids.
Conclusion: Infants with anti-NMDA-receptor antibody encephalitis can present with frank seizures or seizure
mimics. Regardless, prompt recognition and aggressive treatment of anti-NMDA-receptor antibody encephalitis,
while challenging, can quickly arrest deterioration and hasten recovery, thereby, limiting neurologicalmorbidity.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Anti-N-methyl-D-aspartate (NMDA) receptor antibody encephalitis
is an autoimmune disorder presenting subacutelywith prominent aber-
rantmovements and aberrations in behavior associatedwith clinical de-
terioration over several weeks [1,8]. In teenagers and adults, the
presentation and clinical course are well recognized. Prompt recogni-
tion and treatment may reverse the condition, hastening recovery and
limiting neurological morbidity. In very young children, the clinical pre-
sentation is less well-deﬁned and poses a diagnostic challenge particu-
larly when presenting with prominent psychiatric symptoms.
We report 2 young children presenting with seizure-like
movements with CSF-conﬁrmed anti-NMDA-receptor antibody
encephalitis at a single tertiary pediatric institution, where all patients
with neurological symptoms are evaluated by a primary pediatric
neurology team. The tertiary referral children's hospital serves a
population catchment area of approximately three million.-aspartate-receptor; CSF, cere-
Children's Way, Jacksonville, FL
. This is an open access article under2. Reports
2.1. Patient 1
A healthy 21-month-old girl presented with status epilepticus that
was not associated with fever. A few days prior to presentation, the
family noted a change in behaviorwith episodes of terriﬁed appearance.
This was followed by seizures manifesting with orobuccal automatism
and secondarily generalized seizures. Continuous video-EEG demon-
strated clinical and electrographic seizures originating independently
from the right central and left centrotemporal head regions. Seizures
were ultimately controlled with lorazepam, levetiracetam, phenobarbi-
tal, and phenytoin. Six days after admission, she developed agitation
and severe bilateral upper extremity choreiformmovements associated
with oral dyskinesias that failed to respond to risperidone and
tetrabenazine that were reduced after starting memantine.
Initial and subsequent blood counts, general and metabolic serum
panels, urinalysis, and cerebral MR imaging with and without contrast
were normal. Cerebrospinal ﬂuid analysis showed white blood count
of 53/mm3 with predominant lymphocytosis, associated with a normal
glucose and protein. Cerebrospinal and blood cultures were negative.
Antistreptolysin O, antinuclear antibody, lupus anticoagulant, cytoplas-
mic–antineutrophil cytoplasmic antibodies, perinuclear–antineutrophilthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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function studies, creatine kinase, lactic acid, and serum ammonia were
normal as were serum amino and urine organic acids, carnitine, and
acylcarnitine.
A presumptive diagnosis of an autoimmune encephalopathy was
entertained, and a course of immunoglobulin and high dose methyl-
prednisolone was administered. Over the course of ten days, she expe-
rienced improvement in the dyskinesias, and seizures came under
control. The patientwas treatedwith rituximab asmaintenance therapy
but developed an allergic skin reaction. Shewas then treated successful-
ly with cyclophosphamide maintenance therapy.
Three weeks after admission, the CSF that had been initially sent for
anti-NMDA-receptor antibodies, ultimately conﬁrmed the diagnosis.
Over the course of her three months of hospitalization, the patient
clinically improved with marked reduction of seizures and the
disappearance of agitation and choreiform movements. Her neurologi-
cal and developmental functions returned to pre–illness baseline, and
she continued to make improvement in outpatient follow-up without
relapses over the subsequent 5 months.
2.2. Patient 2
A healthy 29-month-old boy presented with 1-week history of bi-
zarre psychiatric symptoms that progressed to behavioral aggression,
insomnia, and disuse of the left upper extremity that were thought to
be seizures.
He had episodic outbursts of excessive, inconsolable crying and dis-
tress that were described “as though he was having nightmares while
awake”. He had delayed sleep onset from his baseline, decreased appe-
tite, decreased activity level, and emesis. Subsequently, he had dysar-
thria with progressively decreasing verbal output to the point of
mutism with preserved comprehension.
Cranial nerves, muscle bulk and strength, and reﬂexes were normal.
His tone was episodically increased in the left upper extremity with
prominent intermittent dystonia and positive Babinski response on
left plantar stimulation. Sensory exam was normal to pin prick and vi-
bration. Gait was initially normal but progressively worsened to signif-
icant ataxia and frequent falls when trying to stand or ambulate
unassisted.
Past history was signiﬁcant for streptococcal-negative pharyngitis
and a motor vehicle accident. The accident occurred at age 19 months
when he sustained a pneumothorax that fully recovered. His develop-
mentwas normal, described as an independent,mild-mannered and ac-
tive toddler. Pregnancy, birth, and family histories were unremarkable.
Because of suspicion of seizures and status epilepticus, an urgent
EEG was obtained that captured movements and showed them to be
nonepileptic seizure mimics consisting of unilateral extremity quasi-
rhythmic movements, and AEDs were withheld.
Cerebrospinal ﬂuid analysis showed 8 WBC and 450 red blood cells
without xanthochromia. Cerebrospinal ﬂuid protein was 26 mg/dL,
and cerebrospinal lactate and glucose were normal. Cerebrospinal
ﬂuid herpes and enterovirus ampliﬁcations were negative. Blood
counts, chemistries, and urine drug screen were unremarkable.
Antistreptolysin O, antinuclear antibody, lupus anticoagulant, cytoplas-
mic–antineutrophil cytoplasmic antibodies, perinuclear–antineutrophil
cytoplasmic antibodies, and antiphospholipid antibody titers, thyroid
function studies, creatine kinase, lactic acid, and serum ammonia were
normal as were serum amino and urine organic acids, carnitine, and
acylcarnitine. Cerebral MRI, EEG, echocardiography, and abdominal ul-
trasound were normal.
Given his progressive neurological deterioration as well as promi-
nentmotor andpsychiatricmanifestations, an empiric diagnosis of auto-
immune-mediated encephalitis was made (and conﬁrmed two weeks
later). An empiric trial of intravenous immunoglobulin of 2 g/kg and
methylprednisolone 30 mg/kg/day were administered over the course
of 5 days. Over the subsequent 6 days, he demonstrated markedimprovement in language, behavior, appetite, and sleep. He was able
to walk without support, and choreoathetoid movements diminished
dramatically. Repeat cerebral and spine MR imaging remained normal.
At this time, results of CSF anti-NMDA-receptor antibodieswere pos-
itive, and hewas placed onmycophenolatewith a plan to treat himwith
immune-modulatory therapy for a full year.
3. Discussion
Two infants presented with aberrant behaviors that were initially
unrecognized as pathological. Seizures were suspected in both infants.
Only with evolution to seizures or seizure mimics including unilateral
quasi-rhythmic movements was neurological involvement suspected.
A negative preliminarywork-up in the face of further neurological dete-
rioration prompted search for an immune-mediated encephalopathy,
which was conﬁrmed serologically to be anti-NMDA-receptor antibody
encephalitis.
This report demonstrates the difﬁculty in identifying behavioral ab-
erration, often a ﬁrst sign of anti-NMDA-receptor antibody encephalitis,
in infants. Seizures or seizuremimicswith psychiatric symptoms should
raise suspicion. Prompt aggressive empiric treatmentwas initiated prior
to CSF conﬁrmation and was based on symptomatology and absence of
common etiologies. Immune therapies rapidly arrested further evolu-
tion and were followed by full clinical recovery. During this one-year
period, we did not identify children outside infancy with the disorder,
although a search of our records for the prior ﬁve years identiﬁed four
older children with anti-NMDA-receptor antibody encephalitis. The
clinical presentation of the older children included a movement
disorder in three and status epilepticus in one who later developed a
movement disorder. Tumors or female preponderance is not observed
in pediatric patients with this diagnosis [1,2,8,10,11].
The incidence of anti-NMDA-receptor antibody encephalitis in pedi-
atrics remains to be deﬁned, although recent studies suggest that it is
the second most common immune-mediated encephalitis, after acute
disseminated encephalomyelitis [3]. In about 70% of patients, the clini-
cal course of anti-NMDA-receptor antibody encephalitis is preceded
by a nonspeciﬁc prodromal stage with fever, headache, nausea, or
upper respiratory symptoms [2]. Psychiatric symptoms include anxiety,
insomnia, paranoia, and agitation [2]; increased agitation anddelusional
thoughts have been reported [5]. Movement disorder features associat-
ed with anti-NMDA-receptor antibody encephalitis include dyskinesias
exacerbated by ambulation and orolingual-facial dyskinesia [2]. Limb
and trunk choreoathetosis, dystonia, and rigidity have also been report-
ed [1,2]; these symptoms ﬁnally progress to a hyperkinetic stage [4].
Autonomic deregulation is more commonly seen in adults, although it
can be seen occasionally in children. Unrecognized, the condition may
progress to a pseudo-vegetative state.
In the very young child, presentation is either one of status epilepti-
cus or behavioral seizuremimics that can be challenging to identify. The
EEG usually shows nonspeciﬁc slowingwithout epileptiformdischarges
or subclinical seizures [2]. Much more difﬁcult to recognize are psychi-
atric symptoms as evidenced by Patient 2, where multiple visits to the
emergency roomwere dismissed as very young child separation anxiety
and temper tantrums.
CerebralMRI is normal in themajority of patients, even late in the dis-
ease course, although nonspeciﬁc T-2 signal hyperintensity may be seen
in white matter and appear to have minimal or no correlation with neu-
rological symptoms [1,2,5]. Cerebral positron emission tomography per-
formed in two children was abnormal with reduced uptake in the basal
ganglia being reported. There is a suggestion that PET may be superior
to cerebral magnetic resonance imaging and electroencephalography
[7], although this ﬁnding remains to be more widely conﬁrmed.
While anti-NMDA-receptor antibodies can be detected in both
serum and CSF, only CSF titers have been correlatedwith severity of dis-
ease [1]. It is hypothesized that immune response initiated by a tumor
or a nonspeciﬁc infectious etiology causes the production of antibodies
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NR1/NR2 subunits of the NMDA-receptor [1,2,6]. Additionally, evidence
of intrathecal synthesis of antibodies has been reported in somepatients
[1,2]. Recurrence of neurological symptoms after HSV encephalitis with
the presence of anti-NMDA-receptor antibodies suggests the infectious
etiology for triggering immune response [8]. A recent study showed that
30% of HSV encephalitis has anti-NMDA-receptor antibodies in serum
and/or CSF [9].
In tumor-negative patients, treatment with high dose steroids and
intravenous immunoglobulin or plasma exchange is the ﬁrst line thera-
py. Relapses occur in 20–25%; the rate may be higher in patients with-
out an associated tumor [6]. Second-line immune therapy includes
rituximab and/or cyclophosphamide [2,6]. One year of immunosuppres-
sion with mycophenolate or azathioprine is recommended to decrease
relapse rates [2]. Aggressive immune therapy has reversed the condi-
tion, even when administered late in the course.
Increased awareness of anti-NMDA-receptor-associated enceph-
alitis has resulted in increasing recognition in the very young child
[1,5,10,11]. The rapid deterioration in our patients prompted a decision
to start empiric treatment before CSF conﬁrmatory results were avail-
able. This resulted in rapid recovery over the course of 2weeks andmin-
imal neurological morbidity.
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